Piramal Enterprises has received an approval for issue of secured Non-Convertible Debentures (NCDs) amounting up to Rs 500 crore. The meeting of Committee of Directors (Funding) held on January 05, 2016 has approved for the same.
Piramal Enterprises is one of the leading players globally in CRAMS (custom research and manufacturing services) as well as in the critical care segment of inhalation and injectable anaesthetics. It also has a strong presence in the OTC segment in India.